Skip to main content
. 2017 Sep 14;2(4):e000214. doi: 10.1136/esmoopen-2017-000214

Figure 1.

Figure 1

Clinical courses of patients. Group A: RECIST PD and clinical PD occurred simultaneously; group B: RECIST PD without clinical PD and discontinued EGFR-TKI; group C: RECIST PD without clinical PD and continued EGFR-TKI; group D: no RECIST or clinical PD but discontinued EGFR-TKI; group E: no RECIST or clinical PD and continuing EGFR-TKI. EGFR, epidermal growth factor receptor; NSCLC, non-small-cell lung carcinoma; PD, progressive disease; RECIST, Response Evaluation Criteria in Solid Tumors; TKI, tyrosine kinase inhibitor.